Paper31228622
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M and 16 others. J Thorac Oncol, 2019. Cited by 381 papers, by iCite.
Cite this record
ConductScience Library. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Papers, record 31228622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31228622
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Transformation, Neoplastic | Major topic |
| Mutation | Major topic |
| Retinoblastoma Binding Proteins | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Ubiquitin-Protein Ligases | Major topic |
| Adenocarcinoma of Lung | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Biomarkers, Tumor | |
| ErbB Receptors | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Lung Neoplasms | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Protein Kinase Inhibitors | |
| Risk Factors | |
| Survival Rate |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R25 CA020449 | NCI NIH HHS | United States | R25CA020449 | PubMed | NIH RePORTER |
| T32 CA009207 | NCI NIH HHS | United States | T32CA009207 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| UL1 TR002384 | NCATS NIH HHS | United States | UL1TR002384 | PubMed and NIH | NIH RePORTER |
| P01 CA129243 | NCI NIH HHS | United States | P01CA129243 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 31558227 | Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep's Clothing. | https://conductscience.org/library/papers/31558227 |
Source PubMed
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16648503 | Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16648503 | PubMed |
| 2 | 16837691 | EGFR mutations in small-cell lung cancers in patients who have never smoked. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16837691 | PubMed |
| 3 | 19131956 | Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. | Nat Protoc | 2009 | https://conductscience.org/library/papers/19131956 | PubMed |
| 4 | 21430269 | Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. | Sci Transl Med | 2011 | https://conductscience.org/library/papers/21430269 | PubMed |
| 5 | 23470965 | Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23470965 | PubMed |
| 6 | 23550210 | Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. | Sci Signal | 2013 | https://conductscience.org/library/papers/23550210 | PubMed |
| 7 | 24436049 | Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24436049 | PubMed |
| 8 | 25122428 | Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/25122428 | PubMed |
| 9 | 25758528 | RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. | Nat Commun | 2015 | https://conductscience.org/library/papers/25758528 | PubMed |
| 10 | 25801821 | Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. | J Mol Diagn | 2015 | https://conductscience.org/library/papers/25801821 | PubMed |
| 11 | 25877892 | Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/25877892 | PubMed |
| 12 | 26168399 | Comprehensive genomic profiles of small cell lung cancer. | Nature | 2015 | https://conductscience.org/library/papers/26168399 | PubMed |
| 13 | 26899170 | DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. | Genome Biol | 2016 | https://conductscience.org/library/papers/26899170 | PubMed |
| 14 | 27270079 | FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. | Nucleic Acids Res | 2016 | https://conductscience.org/library/papers/27270079 | PubMed |
| 15 | 28059767 | Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. | Science | 2017 | https://conductscience.org/library/papers/28059767 | PubMed |
| 16 | 28059768 | SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. | Science | 2017 | https://conductscience.org/library/papers/28059768 | PubMed |
| 17 | 28336552 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28336552 | PubMed |
| 18 | 28498782 | Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28498782 | PubMed |
| 19 | 29151359 | Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29151359 | PubMed |
| 20 | 29180607 | Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29180607 | PubMed |
Cited by275
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 381 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977475 | Transformation to Small-Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR-Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/42977475 | PubMed |
| 42973948 | Epigenetic regulation of cancer stem cell plasticity and relapse competence in EGFR-mutant lung cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42973948 | PubMed |
| 42964587 | Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42964587 | PubMed |
| 42957912 | Genomic landscape of EGFR-TKI resistance: from known mechanisms to unknown resistance. | Cell Oncol (Dordr) | 2026 | https://conductscience.org/library/papers/42957912 | PubMed |
| 42957218 | Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR-mutant Lung Adenocarcinoma. | In Vivo | 2026 | https://conductscience.org/library/papers/42957218 | PubMed |
| 42926199 | Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42926199 | PubMed |
| 42900325 | Histologic and molecular transformation from non-small cell to small cell lung cancer: insights in the era of expanding treatment options. | Med Oncol | 2026 | https://conductscience.org/library/papers/42900325 | PubMed |
| 42856622 | Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report. | Front Oncol | 2026 | https://conductscience.org/library/papers/42856622 | PubMed |
| 42836273 | Genes, fuel, and fate in lung cancer. | Biochem Soc Trans | 2026 | https://conductscience.org/library/papers/42836273 | PubMed |
| 42823758 | Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42823758 | PubMed |
| 42816600 | Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance. | Nat Genet | 2026 | https://conductscience.org/library/papers/42816600 | PubMed |
| 42799075 | Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42799075 | PubMed |
| 42761714 | Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection. | Front Immunol | 2026 | https://conductscience.org/library/papers/42761714 | PubMed |
| 42757013 | Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma. | Front Genet | 2026 | https://conductscience.org/library/papers/42757013 | PubMed |
| 42749760 | Epithelial tumor suppressor deletion promotes neuroendocrine differentiation in bladder cancer and reveals homoharringtonine as a candidate vulnerability. | Oncogene | 2026 | https://conductscience.org/library/papers/42749760 | PubMed |
| 42724635 | Advanced and underlying therapeutic strategies in transformed small cell lung cancer. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42724635 | PubMed |
| 42724630 | Deconvolution of evolutionary architecture unmasks a high-risk, subclonal-rich subtype in treatment-naive small cell lung cancer. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42724630 | PubMed |
| 42698678 | Long-term survival following SCLC transformation after osimertinib resistance in EGFR-mutant NSCLC: Benefit from local surgical resection and osimertinib rechallenge. | Genes Dis | 2027 | https://conductscience.org/library/papers/42698678 | PubMed |
| 42611544 | Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42611544 | PubMed |
| 42588620 | Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588620 | PubMed |
Genes52
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31228622
GET https://conductscience.org/api/papers/v1/31228622/references?page=2